Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1
- 1 August 2011
- journal article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 301 (2), F355-F363
- https://doi.org/10.1152/ajprenal.00729.2010
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone considered a promising therapeutic agent for type 2 diabetes because it stimulates beta cell proliferation and insulin secretion in a glucose-dependent manner. Cumulative evidence supports a role for GLP-1 in modulating renal function; however, the mechanisms by which GLP-1 induces diuresis and natriuresis have not been completely established. This study aimed to define the cellular and molecular mechanisms mediating the renal effects of GLP-1. GLP-1 (1 μg·kg−1·min−1) was intravenously administered in rats for the period of 60 min. GLP-1-infused rats displayed increased urine flow, fractional excretion of sodium, potassium, and bicarbonate compared with those rats that received vehicle (1% BSA/saline). GLP-1-induced diuresis and natriuresis were also accompanied by increases in renal plasma flow and glomerular filtration rate. Real-time RT-PCR in microdissected rat nephron segments revealed that GLP-1 receptor-mRNA expression was restricted to glomerulus and proximal convoluted tubule. In rat renal proximal tubule, GLP-1 significantly reduced Na+/H+ exchanger isoform 3 (NHE3)-mediated bicarbonate reabsorption via a protein kinase A (PKA)-dependent mechanism. Reduced proximal tubular bicarbonate flux rate was associated with a significant increase of NHE3 phosphorylation at the PKA consensus sites in microvillus membrane vesicles. Taken together, these data suggest that GLP-1 has diuretic and natriuretic effects that are mediated by changes in renal hemodynamics and by downregulation of NHE3 activity in the renal proximal tubule. Moreover, our findings support the view that GLP-1-based agents may have a potential therapeutic use not only as antidiabetic drugs but also in hypertension and other disorders of sodium retention.Keywords
This publication has 39 references indexed in Scilit:
- Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHRAmerican Journal of Physiology-Renal Physiology, 2010
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapiesJournal of the American Society of Hypertension, 2009
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice modelBiochemical and Biophysical Research Communications, 2009
- Regulatory Binding Partners and Complexes of NHE3Physiological Reviews, 2007
- Biologic actions and therapeutic potential of the proglucagon-derived peptidesNature Clinical Practice Endocrinology & Metabolism, 2005
- ENTEROGLUCAGONAnnual Review of Physiology, 1997
- Diabetes Mellitus and Associated Hypertension, Vascular Disease, and NephropathyHypertension, 1995
- Diabetes mellitus and hypertension.Hypertension, 1992
- Energy-dependence of phlorizin binding to isolated renal microvillus membranesThe Journal of Membrane Biology, 1978
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970